The advent of The Affordable Care Act (Obamacare) is on the horizon as the healthcare sector of the market continues its strong rally. With new Food and Drug Administration (FDA) regulatory easing, congressional bills, and The Obama Administration directive in…
Bullish Archived Articles
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
$AVEO Due Diligence: Catalyst: Adcomm May 2nd
2 days ago, I issued a bullish chart alert for $Aveo. Some basic DD on Aveo: First off, one of the best articles covering Aveo’s tivozanib, which is designed as a front line treatment for metastatic renal cell carcinoma (RCC)…
Antares Pharma ($ATRS) Technical Long Trade Thesis and Chart
Antares Pharma (ATRS) is being set up to run to at least $3.85, Thesis follows below; The chart above shows “quiet” accumulation. The purple line is the accumulation, notice for the first time, the accumulation points up, MACD and RSI…
Aveo Chart Technicals
I see a strong chart set up from above. We see a nice continuation pattern, super strong accumulation and RSI, both showing a cup and handle type pattern.Therefore, my short term trade target opinion is $8.25 Aveo has an…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
Significant catalysts and an unfortunate PR mistake present an opportunity in AcelRx Pharmaceuticals.
With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
Download $TSRX Analyst Report
Download Analyst Report on $TSRX HERE-TSRX-SunTrust-Robinson-Humphrey-Feb-12
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
